Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
June 30, 2014
Tokyo, Japan, June 30, 2014 --- Kyowa Hakko Kirin Co, Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced that it has been re-filed an application to Japan's Ministry of Health, Labour and Welfare ("MHLW") seeking approval for additional indication for untreated CCR4-positive adult T-cell leukemia-lymphoma (ATL) of Mogamulizumab (brand name: POTELIGEO® Injection 20 mg).
Mogamulizumab was launched in Japan with the brand name "POTELIGEO® Injection 20 mg" on May 29, 2012 for the treatment of patients with relapsed or refractory CCR4-positive ATL. On March 17, 2014, Kyowa Hakko Kirin has received approval for additional indication for relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
On July 19, 2013, Kyowa Hakko Kirin filed a supplemental new drug application seeking approval for additional indication of Mogamulizumab for patients including untreated CCR4-positive ATL. However, through consultation with the regulatory agency, it was determined that additional information is needed to support approval in untreated CCR4-positive ATL, and Kyowa Hakko Kirin had decided to temporarily withdraw submission for Mogamulizumab use in this indication from the application. Recently, through consultation with the regulatory agency, additional information for review will be available, Kyowa Hakko Kirin has decided to re-file an application.
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
You can see this table by scrolling horizontally.
| Indication | Status | Applicable Locations |
|---|---|---|
| Relapsed or refractory CCR4-positive ATL, PTCL and CTCL | Available | Japan |
| Untreated CCR4-positive ATL | Now re-filed | Japan |
| Relapsed or refractory ATL | Phase 2 trial | United States, Europe, Others |
| Relapsed or refractory CTCL | Phase 3 trial | United States, Europe, Japan |
| Relapsed or refractory CCR4-positive PTCL | Phase 2 trial | Europe |
- About CC chemokine receptor 4 (CCR4)
- CCR4 is one of the chemokine receptors involved in leukocyte migration, selectively expressed in type 2 helper T (Th2) cells and regulatory T (Treg) cells. CCR4 is also shown to be over-expressed in certain hematological malignancies.
- About adult T-cell leukemia-lymphoma (ATL)
- ATL is a peripheral T-cell malignancy and the retrovirus HTLV-1 is thought to be involved in its onset. Estimates show that around 1,150 new cases occur every year in Japan. In Japan ATL is generally treated with combination chemotherapy, such as mLSG15, but there are currently no therapeutic methods with the potential of providing a cure for ATL, although researchers are actively looking into other methods than transplantation. For relapsed/refractory cases, various chemotherapy regimens based on malignant lymphoma therapies are currently used, but an effective treatment method has yet to be established.
- About peripheral T-cell lymphoma (PTCL)
- Non-Hodgkin lymphomas account for the majority of malignant lymphoma cases and can be broadly divided into disease of B-cell origin and disease of T/natural killer (NK)-cell origin. Disease of T/NK-cell origin can be classified according to the main lesion site into nodal, extranodal, cutaneous, and leukemic disease. PTCL is a general term describing nodal and extranodal disease of T/NK-cell origin.
- About cutaneous T-cell lymphoma (CTCL)
- CTCL is a rare, low grade type of non-Hodgkin's lymphoma. CTCL is one of the most common forms of T-cell lymphoma. The two most common types of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS). MF does not look the same in all patients and may present as skin patches, plaques, and tumors. SS in an advanced form of MF and includes the presence of malignant lymphocytes in the blood.
Contact:
Kyowa Hakko Kirin
Media Contact:
+81-3-3282-1903
or
Investors:
+81-3-3282-0009